002332.SZ
002332.SZ
CNE100000K64
XJZY
Loading chart...

Company Profile

Zhejiang Xianju Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of steroid raw materials and preparations in China and internationally. The company offers cortical steriod, gynecology and family planning, respiratory, and dermatological drugs, as well as anaesthetic and muscle relaxants; and active pharmaceutical ingredients and intermediates. It is also involved in the provision of contract development and manufacturing organization; contract manufacturing organization; technical; technology development; and inspection and testing services. The company was founded in 1972 and is headquartered in Xianju, China.

Related stocks

600789.SS
600789.SS • China
SHANDONG LUKANG PHARMACEUTICAL
8.28 CNY
1.29B USD 1Y -15.3%
600129.SS
600129.SS • China
CHONGQING TAIJI IND
13.97 CNY
1.15B USD 1Y -36.3%
600993.SS
600993.SS • China
MAYINGLONG PHARMACEUTICAL GP CO
22.95 CNY
1.48B USD 1Y -15%
002349.SZ
002349.SZ • China
JINGHUA PHARM
9.24 CNY
1.15B USD 1Y +28.3%
600812.SS
600812.SS • China
NORTH CHINA PHARMACEUTICAL CO
6.03 CNY
1.55B USD 1Y +1.5%
002275.SZ
002275.SZ • China
GLSJ
12.35 CNY
1.09B USD 1Y -16%
301263.SZ
301263.SZ • China
TEK
19.14 CNY
1.22B USD 1Y -31.8%
600572.SS
600572.SS • China
ZHEJIANG CONBA PHARMACEUTICAL C
4.41 CNY
1.68B USD 1Y +0.5%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
32.9% p.a.
Max Drawdown (5Y)
-47.9%
Sharpe Ratio (5Y)
-0.22
Beta Factor
0.19
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (32.9% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -55.6% in the extended horizon.
ende